The global Pharmacovigilance Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmacovigilance Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacovigilance Services.
Report Scope
The Pharmacovigilance Services market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacovigilance Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacovigilance Services companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
PrimeVigilance
Quanticate
ProPharma
Parexel
Accenture
SOTERIUS
SGS
Medpace
PPD
QVigilance
Freyr Solutions
Navitas Life Sciences
MMS Holdings
Amarex
Astrix Technology Group
Cambridge Regulatory Services
CROMSOURCE
APCER Life Sciences
Pharmya
A+Science
Midas Pharma
George Clinical
Syneos Health
INPHARMATIS
Taimei Technology
Extedo
WCG Clinical
Segment by Type
Adverse Event Case Management
Aggregate Reporting
Signal Intelligence
Risk Management
Segment by Application
Biotechnology and Pharmaceuticals
Contract Research Organization
Hospital
KPO / BPO
Healthcare Institutions
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacovigilance Services companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pharmacovigilance Services 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Adverse Event Case Management
1.2.3 Aggregate Reporting
1.2.4 Signal Intelligence
1.2.5 Risk Management
1.3 麻豆原创 by Application
1.3.1 Global Pharmacovigilance Services 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology and Pharmaceuticals
1.3.3 Contract Research Organization
1.3.4 Hospital
1.3.5 KPO / BPO
1.3.6 Healthcare Institutions
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmacovigilance Services 麻豆原创 Perspective (2019-2030)
2.2 Pharmacovigilance Services Growth Trends by Region
2.2.1 Global Pharmacovigilance Services 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmacovigilance Services Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Pharmacovigilance Services Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Pharmacovigilance Services 麻豆原创 Dynamics
2.3.1 Pharmacovigilance Services Industry Trends
2.3.2 Pharmacovigilance Services 麻豆原创 Drivers
2.3.3 Pharmacovigilance Services 麻豆原创 Challenges
2.3.4 Pharmacovigilance Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacovigilance Services Players by Revenue
3.1.1 Global Top Pharmacovigilance Services Players by Revenue (2019-2024)
3.1.2 Global Pharmacovigilance Services Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Pharmacovigilance Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacovigilance Services Revenue
3.4 Global Pharmacovigilance Services 麻豆原创 Concentration Ratio
3.4.1 Global Pharmacovigilance Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacovigilance Services Revenue in 2023
3.5 Pharmacovigilance Services Key Players Head office and Area Served
3.6 Key Players Pharmacovigilance Services Product Solution and Service
3.7 Date of Enter into Pharmacovigilance Services 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacovigilance Services Breakdown Data by Type
4.1 Global Pharmacovigilance Services Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Pharmacovigilance Services Forecasted 麻豆原创 Size by Type (2025-2030)
5 Pharmacovigilance Services Breakdown Data by Application
5.1 Global Pharmacovigilance Services Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Pharmacovigilance Services Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Pharmacovigilance Services 麻豆原创 Size (2019-2030)
6.2 North America Pharmacovigilance Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pharmacovigilance Services 麻豆原创 Size by Country (2019-2024)
6.4 North America Pharmacovigilance Services 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmacovigilance Services 麻豆原创 Size (2019-2030)
7.2 Europe Pharmacovigilance Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pharmacovigilance Services 麻豆原创 Size by Country (2019-2024)
7.4 Europe Pharmacovigilance Services 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacovigilance Services 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Pharmacovigilance Services 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pharmacovigilance Services 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Pharmacovigilance Services 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmacovigilance Services 麻豆原创 Size (2019-2030)
9.2 Latin America Pharmacovigilance Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pharmacovigilance Services 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Pharmacovigilance Services 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacovigilance Services 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Pharmacovigilance Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pharmacovigilance Services 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Pharmacovigilance Services 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 PrimeVigilance
11.1.1 PrimeVigilance Company Detail
11.1.2 PrimeVigilance Business Overview
11.1.3 PrimeVigilance Pharmacovigilance Services Introduction
11.1.4 PrimeVigilance Revenue in Pharmacovigilance Services Business (2019-2024)
11.1.5 PrimeVigilance Recent Development
11.2 Quanticate
11.2.1 Quanticate Company Detail
11.2.2 Quanticate Business Overview
11.2.3 Quanticate Pharmacovigilance Services Introduction
11.2.4 Quanticate Revenue in Pharmacovigilance Services Business (2019-2024)
11.2.5 Quanticate Recent Development
11.3 ProPharma
11.3.1 ProPharma Company Detail
11.3.2 ProPharma Business Overview
11.3.3 ProPharma Pharmacovigilance Services Introduction
11.3.4 ProPharma Revenue in Pharmacovigilance Services Business (2019-2024)
11.3.5 ProPharma Recent Development
11.4 Parexel
11.4.1 Parexel Company Detail
11.4.2 Parexel Business Overview
11.4.3 Parexel Pharmacovigilance Services Introduction
11.4.4 Parexel Revenue in Pharmacovigilance Services Business (2019-2024)
11.4.5 Parexel Recent Development
11.5 Accenture
11.5.1 Accenture Company Detail
11.5.2 Accenture Business Overview
11.5.3 Accenture Pharmacovigilance Services Introduction
11.5.4 Accenture Revenue in Pharmacovigilance Services Business (2019-2024)
11.5.5 Accenture Recent Development
11.6 SOTERIUS
11.6.1 SOTERIUS Company Detail
11.6.2 SOTERIUS Business Overview
11.6.3 SOTERIUS Pharmacovigilance Services Introduction
11.6.4 SOTERIUS Revenue in Pharmacovigilance Services Business (2019-2024)
11.6.5 SOTERIUS Recent Development
11.7 SGS
11.7.1 SGS Company Detail
11.7.2 SGS Business Overview
11.7.3 SGS Pharmacovigilance Services Introduction
11.7.4 SGS Revenue in Pharmacovigilance Services Business (2019-2024)
11.7.5 SGS Recent Development
11.8 Medpace
11.8.1 Medpace Company Detail
11.8.2 Medpace Business Overview
11.8.3 Medpace Pharmacovigilance Services Introduction
11.8.4 Medpace Revenue in Pharmacovigilance Services Business (2019-2024)
11.8.5 Medpace Recent Development
11.9 PPD
11.9.1 PPD Company Detail
11.9.2 PPD Business Overview
11.9.3 PPD Pharmacovigilance Services Introduction
11.9.4 PPD Revenue in Pharmacovigilance Services Business (2019-2024)
11.9.5 PPD Recent Development
11.10 QVigilance
11.10.1 QVigilance Company Detail
11.10.2 QVigilance Business Overview
11.10.3 QVigilance Pharmacovigilance Services Introduction
11.10.4 QVigilance Revenue in Pharmacovigilance Services Business (2019-2024)
11.10.5 QVigilance Recent Development
11.11 Freyr Solutions
11.11.1 Freyr Solutions Company Detail
11.11.2 Freyr Solutions Business Overview
11.11.3 Freyr Solutions Pharmacovigilance Services Introduction
11.11.4 Freyr Solutions Revenue in Pharmacovigilance Services Business (2019-2024)
11.11.5 Freyr Solutions Recent Development
11.12 Navitas Life Sciences
11.12.1 Navitas Life Sciences Company Detail
11.12.2 Navitas Life Sciences Business Overview
11.12.3 Navitas Life Sciences Pharmacovigilance Services Introduction
11.12.4 Navitas Life Sciences Revenue in Pharmacovigilance Services Business (2019-2024)
11.12.5 Navitas Life Sciences Recent Development
11.13 MMS Holdings
11.13.1 MMS Holdings Company Detail
11.13.2 MMS Holdings Business Overview
11.13.3 MMS Holdings Pharmacovigilance Services Introduction
11.13.4 MMS Holdings Revenue in Pharmacovigilance Services Business (2019-2024)
11.13.5 MMS Holdings Recent Development
11.14 Amarex
11.14.1 Amarex Company Detail
11.14.2 Amarex Business Overview
11.14.3 Amarex Pharmacovigilance Services Introduction
11.14.4 Amarex Revenue in Pharmacovigilance Services Business (2019-2024)
11.14.5 Amarex Recent Development
11.15 Astrix Technology Group
11.15.1 Astrix Technology Group Company Detail
11.15.2 Astrix Technology Group Business Overview
11.15.3 Astrix Technology Group Pharmacovigilance Services Introduction
11.15.4 Astrix Technology Group Revenue in Pharmacovigilance Services Business (2019-2024)
11.15.5 Astrix Technology Group Recent Development
11.16 Cambridge Regulatory Services
11.16.1 Cambridge Regulatory Services Company Detail
11.16.2 Cambridge Regulatory Services Business Overview
11.16.3 Cambridge Regulatory Services Pharmacovigilance Services Introduction
11.16.4 Cambridge Regulatory Services Revenue in Pharmacovigilance Services Business (2019-2024)
11.16.5 Cambridge Regulatory Services Recent Development
11.17 CROMSOURCE
11.17.1 CROMSOURCE Company Detail
11.17.2 CROMSOURCE Business Overview
11.17.3 CROMSOURCE Pharmacovigilance Services Introduction
11.17.4 CROMSOURCE Revenue in Pharmacovigilance Services Business (2019-2024)
11.17.5 CROMSOURCE Recent Development
11.18 APCER Life Sciences
11.18.1 APCER Life Sciences Company Detail
11.18.2 APCER Life Sciences Business Overview
11.18.3 APCER Life Sciences Pharmacovigilance Services Introduction
11.18.4 APCER Life Sciences Revenue in Pharmacovigilance Services Business (2019-2024)
11.18.5 APCER Life Sciences Recent Development
11.19 Pharmya
11.19.1 Pharmya Company Detail
11.19.2 Pharmya Business Overview
11.19.3 Pharmya Pharmacovigilance Services Introduction
11.19.4 Pharmya Revenue in Pharmacovigilance Services Business (2019-2024)
11.19.5 Pharmya Recent Development
11.20 A+Science
11.20.1 A+Science Company Detail
11.20.2 A+Science Business Overview
11.20.3 A+Science Pharmacovigilance Services Introduction
11.20.4 A+Science Revenue in Pharmacovigilance Services Business (2019-2024)
11.20.5 A+Science Recent Development
11.21 Midas Pharma
11.21.1 Midas Pharma Company Detail
11.21.2 Midas Pharma Business Overview
11.21.3 Midas Pharma Pharmacovigilance Services Introduction
11.21.4 Midas Pharma Revenue in Pharmacovigilance Services Business (2019-2024)
11.21.5 Midas Pharma Recent Development
11.22 George Clinical
11.22.1 George Clinical Company Detail
11.22.2 George Clinical Business Overview
11.22.3 George Clinical Pharmacovigilance Services Introduction
11.22.4 George Clinical Revenue in Pharmacovigilance Services Business (2019-2024)
11.22.5 George Clinical Recent Development
11.23 Syneos Health
11.23.1 Syneos Health Company Detail
11.23.2 Syneos Health Business Overview
11.23.3 Syneos Health Pharmacovigilance Services Introduction
11.23.4 Syneos Health Revenue in Pharmacovigilance Services Business (2019-2024)
11.23.5 Syneos Health Recent Development
11.24 INPHARMATIS
11.24.1 INPHARMATIS Company Detail
11.24.2 INPHARMATIS Business Overview
11.24.3 INPHARMATIS Pharmacovigilance Services Introduction
11.24.4 INPHARMATIS Revenue in Pharmacovigilance Services Business (2019-2024)
11.24.5 INPHARMATIS Recent Development
11.25 Taimei Technology
11.25.1 Taimei Technology Company Detail
11.25.2 Taimei Technology Business Overview
11.25.3 Taimei Technology Pharmacovigilance Services Introduction
11.25.4 Taimei Technology Revenue in Pharmacovigilance Services Business (2019-2024)
11.25.5 Taimei Technology Recent Development
11.26 Extedo
11.26.1 Extedo Company Detail
11.26.2 Extedo Business Overview
11.26.3 Extedo Pharmacovigilance Services Introduction
11.26.4 Extedo Revenue in Pharmacovigilance Services Business (2019-2024)
11.26.5 Extedo Recent Development
11.27 WCG Clinical
11.27.1 WCG Clinical Company Detail
11.27.2 WCG Clinical Business Overview
11.27.3 WCG Clinical Pharmacovigilance Services Introduction
11.27.4 WCG Clinical Revenue in Pharmacovigilance Services Business (2019-2024)
11.27.5 WCG Clinical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
PrimeVigilance
Quanticate
ProPharma
Parexel
Accenture
SOTERIUS
SGS
Medpace
PPD
QVigilance
Freyr Solutions
Navitas Life Sciences
MMS Holdings
Amarex
Astrix Technology Group
Cambridge Regulatory Services
CROMSOURCE
APCER Life Sciences
Pharmya
A+Science
Midas Pharma
George Clinical
Syneos Health
INPHARMATIS
Taimei Technology
Extedo
WCG Clinical
听
听
*If Applicable.
